window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : May 13, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Therapeutic Areas

  • Advanced Therapies,Biotech & Pharma Business,Drug Discovery & Development,Therapeutic Areas

    etherna intratumoral mRNA/LNP platform advances toward IND studies in non-melanoma skin cancer

    etherna, a biotech company specialising in mRNA and lipid nanoparticle [...]

    May 5, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Fennec presents real world data on Pedmark use in head and neck cancer

    Fennec Pharmaceuticals has presented real world data supporting the integration [...]

    May 5, 2026
  • Advanced Therapies,Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Almirall meets guidance with 12.4% net sales growth and dermatology portfolio progress in 2025

    Almirall delivered net sales growth of 12.4% in 2025, surpassing [...]

    May 5, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Patients with Crohn’s disease maintain steroid-free remission for three years with Lilly’s Omvoh (mirikizumab)

    Long-term VIVID-2 data show more than 90% of patients with [...]

    May 5, 2026
  • Central Nervous System,Clinical & Regulatory,Drug Discovery & Development,Opinion & Events,Therapeutic Areas

    International Brain Health Conference 2026 to focus on early intervention before dementia

    The inaugural International Brain Health Conference 2026 in Edinburgh will [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Manufacturing & Supply Chain,Therapeutic Areas

    Hansa Biopharma’s BLA for imlifidase accepted by FDA

    Hansa Biopharma’s Biologics License Application (BLA) for imlifidase has been [...]

    May 5, 2026
  • Biotech & Pharma Business,Central Nervous System,Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    Lario receives $2.4M from MJFF and Wellcome to expand neuronal calcium channel research in CNS disorders

    Lario Therapeutics awarded $2.4M by The Michael J. Fox Foundation [...]

    May 5, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Affibody licensee Rallybio reports Phase 1 data showing sustained complement inhibition with RLYB116

    Affibody has reported positive Phase 1 data from its licensee [...]

    May 5, 2026
  • Biotech & Pharma Business,Digital & Data,Drug Discovery & Development,Therapeutic Areas

    Evogene partners QUT on AI drug discovery for lung cancer resistance

    Evogene Ltd has partnered with Queensland University of Technology to [...]

    May 5, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Sensei acquires Faeth and secures $200M to advance PIKTOR in endometrial and breast cancer

    Sensei Biotherapeutics has acquired Faeth Therapeutics and announced a concurrent [...]

    May 5, 2026
Previous789Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Click Therapeutics secures $50M from Boehringer Ingelheim for schizophrenia digital therapy
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Digital & Data, Pharmaceuticals and therapeutics, Therapeutic Areas
  • Kainova Therapeutics doses first patient in Europe in phase 1/2 anti-CCR8 antibody trial
    Categories: Clinical & Regulatory, Therapeutic Areas
  • START appoints Salwan Al Mutar to lead clinical research in Dallas-Fort Worth
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top